2Settimana·

Keep $JNJ (-1,21%) in mind if you're investing for solid income...consistent and growing history of dividend payouts.


The company’s robust financials, including a triple-A credit rating and significant cash reserves, position it well for sustained growth and reduced legal risks.

attachment
14
1 Commento

immagine del profilo
I'm primarily invested because I hope they will do the same with the J&J medtech segment as they did with Kenvue and end up like Novartis
1

Partecipa alla conversazione